Journal of Gastroenterology

, Volume 46, Issue 4, pp 545–555 | Cite as

Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C

  • Kazuaki ChayamaEmail author
  • C. Nelson Hayes
  • Kentaro Yoshioka
  • Hisataka Moriwaki
  • Takashi Okanoue
  • Shotaro Sakisaka
  • Tetsuo Takehara
  • Makoto Oketani
  • Joji Toyota
  • Namiki Izumi
  • Yoichi Hiasa
  • Akihiro Matsumoto
  • Hideyuki Nomura
  • Masataka Seike
  • Yoshiyuki Ueno
  • Hiroshi Yotsuyanagi
  • Hiromitsu Kumada
Original Article—Liver, Pancreas, and Biliary Tract



Treatment of genotype 1b chronic hepatitis C virus (HCV) infection has been improved by extending peg-interferon plus ribavirin combination therapy to 72 weeks, but predictive factors are needed to identify those patients who are likely to respond to long-term therapy.


We analyzed amino acid (aa) substitutions in the core protein and the interferon sensitivity determining region (ISDR) of nonstructural protein (NS) 5A in 840 genotype 1b chronic hepatitis C patients with high viral load. We used logistic regression and classification and regression tree (CART) analysis to identify predictive factors for sustained virological response (SVR) for patients undergoing 72 weeks of treatment.


When patients were separately analyzed by treatment duration using multivariate logistic regression, several factors, including sex, age, viral load, and core aa70 and ISDR substitutions (P = 0.0003, P = 0.02, P = 0.01, P = 0.0001, and P = 0.0004, respectively) were significant predictive factors for SVR with 48 weeks of treatment, whereas age, previous interferon treatment history, and ISDR substitutions (P = 0.03, P = 0.01, and P = 0.02, respectively) were the only significant predictive factors with 72 weeks of treatment. Using CART analysis, a decision tree was generated that identified age, cholesterol, sex, treatment length, and aa70 and ISDR substitutions as the most important predictive factors. The CART model had a sensitivity of 69.2% and specificity of 60%, with a positive predictive value of 68.4%.


Complementary statistical and data mining approaches were used to identify a subgroup of patients likely to benefit from 72 weeks of therapy.


CART analysis Core protein Decision tree ISDR LDL cholesterol 



Hepatitis C virus


Interferon sensitivity determining region


Classification and regression tree analysis


Sustained virological response


Non-viral response



This work was supported in part by Grants-in-Aid for scientific research and development from the Ministry of Health, Labor and Welfare and Ministry of Education, Culture, Sports, Science and Technology, Government of Japan. We thank Sakura Akamatsu and Mika Tsuzuno for their assistance.

Conflict of interest

None of the authors have conflicts of interest to declare.

Supplementary material

535_2010_358_MOESM1_ESM.ppt (124 kb)
Figure S1. Selection of patients. 840 patients were selected out of 1,425 patients who were treated with PEG-IFN plus ribavirin combination therapy. Patients were divided into two groups based on the duration of treatment, 48 weeks (619) and 72 weeks (221) (PPT 27 kb)
535_2010_358_MOESM2_ESM.ppt (195 kb)
Figure S2. Receiver operating characteristic curve for CART analysis and multivariate logistic regression. The area under the curve is 0.677 for the CART analysis and 0.696 for the logistic regression analysis (PPT 249 kb)


  1. 1.
    Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26:15S–20S.PubMedCrossRefGoogle Scholar
  2. 2.
    Di Bisceglie AM. Hepatitis C. Lancet. 1998;351:351–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(Suppl 1):9–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.PubMedGoogle Scholar
  7. 7.
    Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009;150:528–40.PubMedGoogle Scholar
  8. 8.
    Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086–97.PubMedCrossRefGoogle Scholar
  9. 9.
    Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology. 2007;46:1688–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010;138:503–12. 12 e1.PubMedCrossRefGoogle Scholar
  12. 12.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006;78:83–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44:952–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol. 2009;81:640–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, et al. Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino acid 70 in the core region. Intervirology. 2010;53:105–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81:452–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002;76:11079–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Jenke AC, Moser S, Orth V, Zilbauer M, Gerner P, Wirth S. Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy. J Viral Hepat. 2009;16:853–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Layden-Almer JE, Kuiken C, Ribeiro RM, Kunstman KJ, Perelson AS, Layden TJ, et al. Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis. 2005;192:1078–87.PubMedCrossRefGoogle Scholar
  21. 21.
    Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, et al. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol. 2004;74:41–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez-Barcons M, Franco S, et al. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol. 2005;86:1067–75.PubMedCrossRefGoogle Scholar
  23. 23.
    Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20:23–38.PubMedCrossRefGoogle Scholar
  24. 24.
    El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008;48:38–47.PubMedCrossRefGoogle Scholar
  25. 25.
    El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol Immunol. 2007;51:471–82.PubMedGoogle Scholar
  26. 26.
    Yang SS, Lai MY, Chen DS, Chen GH, Kao JH. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int. 2003;23:426–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis—diagnosis, grading and staging. Hepatology. 1994;19:1513–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Chayama K, Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, et al. Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype. J Virol Methods. 2001;95:33–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A. 1990;87:9524–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis-C virus 1b – sensitivity to interferon is conferred by amino-acid substitutions in the NS5A region. J Clin Invest. 1995;96:224–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77–81.PubMedCrossRefGoogle Scholar
  32. 32.
    Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. The WEKA data mining software: an update. SIGKDD Explor. 2009;11:10–8.CrossRefGoogle Scholar
  33. 33.
    Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16:75–90.PubMedCrossRefGoogle Scholar
  34. 34.
    Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010;52:1201–7.Google Scholar
  35. 35.
    Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Herrmann E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol. 2010;8:884–90.Google Scholar
  36. 36.
    Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, et al. Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res. 2010;40:135–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res. 2010;40:251–60.PubMedCrossRefGoogle Scholar
  38. 38.
    El Malki HO, El Mejdoubi Y, Souadka A, Mohsine R, Ifrine L, Abouqal R, et al. Predictive model of biliocystic communication in liver hydatid cysts using classification and regression tree analysis. BMC Surg. 2010;10:16.PubMedCrossRefGoogle Scholar
  39. 39.
    Augustin S, Muntaner L, Altamirano JT, Gonzalez A, Saperas E, Dot J, et al. Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. Clin Gastroenterol Hepatol. 2009;7:1347–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Kazuaki Chayama
    • 1
    Email author
  • C. Nelson Hayes
    • 1
  • Kentaro Yoshioka
    • 2
  • Hisataka Moriwaki
    • 3
  • Takashi Okanoue
    • 4
  • Shotaro Sakisaka
    • 5
  • Tetsuo Takehara
    • 6
  • Makoto Oketani
    • 7
  • Joji Toyota
    • 8
  • Namiki Izumi
    • 9
  • Yoichi Hiasa
    • 10
  • Akihiro Matsumoto
    • 11
  • Hideyuki Nomura
    • 12
  • Masataka Seike
    • 13
  • Yoshiyuki Ueno
    • 14
  • Hiroshi Yotsuyanagi
    • 15
  • Hiromitsu Kumada
    • 16
  1. 1.Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical SciencesHiroshima UniversityHiroshimaJapan
  2. 2.Division of Liver, Biliary Tract and Pancreas Diseases, Department of Internal MedicineFujita Health UniversityNagoyaJapan
  3. 3.Department of GastroenterologyGifu University Graduate School of MedicineGifuJapan
  4. 4.Department of Gastroenterology and HepatologySaiseikai Suita HospitalSuitaJapan
  5. 5.Department of Gastroenterology and MedicineFukuoka University School of MedicineFukuokaJapan
  6. 6.Department of Gastroenterology and HepatologyOsaka University Graduate School of MedicineOsakaJapan
  7. 7.Department of Digestive and Life-Style Related Disease, Health Research Course, Human and Environmental SciencesKagoshima University Graduate School of Medical and Dental SciencesKagoshimaJapan
  8. 8.Department of GastroenterologySapporo Kosei General HospitalSapporoJapan
  9. 9.Division of Gastroenterology and HepatologyMusashino Red Cross HospitalMusashinoJapan
  10. 10.Department of Gastroenterology and MetabologyEhime University Graduate School of MedicineMatsuyamaJapan
  11. 11.Department of MedicineShinshu University School of MedicineMatsumotoJapan
  12. 12.The Center for Liver DiseasesShin-Kokura HospitalKokuraJapan
  13. 13.Department of Internal Medicine 1, Faculty of MedicineOita UniversityOitaJapan
  14. 14.Division of GastroenterologyTohoku University Graduate School of MedicineSendaiJapan
  15. 15.Department of Internal Medicine, Graduate School of MedicineUniversity of TokyoTokyoJapan
  16. 16.Department of HepatologyToranomon HospitalTokyoJapan

Personalised recommendations